Bortezomib will enhance the degree or outcome of flibanserin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Greater flibanserin adverse outcomes might manifest if coadministered with numerous weak CYP3A4 inhibitors. Procedure results in peripheral neuropathy (predominantly sensory); however, cases of severe sensory and motor peripheral neuropathy are ... https://deaninrux.blogozz.com/26505479/the-3-cgamp-sodium-diaries